121 related articles for article (PubMed ID: 8893869)
1. Bladder cancer screening.
Kryger JV; Messing E
Semin Oncol; 1996 Oct; 23(5):585-97. PubMed ID: 8893869
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of hematuria home screening for bladder cancer in men.
Messing EM; Madeb R; Young T; Gilchrist KW; Bram L; Greenberg EB; Wegenke JD; Stephenson L; Gee J; Feng C
Cancer; 2006 Nov; 107(9):2173-9. PubMed ID: 17029275
[TBL] [Abstract][Full Text] [Related]
3. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
[TBL] [Abstract][Full Text] [Related]
4. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
5. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
Lotan Y; Svatek RS; Sagalowsky AI
Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
[TBL] [Abstract][Full Text] [Related]
6. Can hematuria be a predictor as well as a symptom or sign of bladder cancer?
Friedman GD; Carroll PR; Cattolica EV; Hiatt RA
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):993-6. PubMed ID: 8959322
[TBL] [Abstract][Full Text] [Related]
7. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
8. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
9. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy.
Hedelin H; Jonsson K; Salomonsson K; Boman H
Scand J Urol Nephrol; 2006; 40(1):26-30. PubMed ID: 16452052
[TBL] [Abstract][Full Text] [Related]
10. Markers of detection.
Messing E
Urol Oncol; 2007; 25(4):344-7. PubMed ID: 17628306
[TBL] [Abstract][Full Text] [Related]
11. Superficial bladder cancer: part 1. Update on etiology, classification and natural history.
Josephson DY; Pasin E; Stein JP
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1723-34. PubMed ID: 17181486
[TBL] [Abstract][Full Text] [Related]
12. Current state of screening for bladder cancer.
Madeb R; Golijanin D; Knopf J; Messing EM
Expert Rev Anticancer Ther; 2007 Jul; 7(7):981-7. PubMed ID: 17627458
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer: epidemiology, staging and grading, and diagnosis.
Kirkali Z; Chan T; Manoharan M; Algaba F; Busch C; Cheng L; Kiemeney L; Kriegmair M; Montironi R; Murphy WM; Sesterhenn IA; Tachibana M; Weider J
Urology; 2005 Dec; 66(6 Suppl 1):4-34. PubMed ID: 16399414
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.
Svatek RS; Sagalowsky AI; Lotan Y
Urol Oncol; 2006; 24(4):338-43. PubMed ID: 16818188
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
16. Urothelial cancer biomarkers for detection and surveillance.
Liou LS
Urology; 2006 Mar; 67(3 Suppl 1):25-33; discussion 33-4. PubMed ID: 16530072
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer in Sri Lanka: experience from a tertiary referral center.
Goonewardena SA; De Silva WA; De Silva MV
Int J Urol; 2004 Nov; 11(11):969-72. PubMed ID: 15509199
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
19. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
20. Screening and monitoring for bladder cancer: refining the use of NMP22.
Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
